Investigating transcription factors in development
- Official title: Alterations of oncogenic transcription factors as therapeutic targets in paediatric gliomas
- Lead researchers: Dr Rameen Beroukhim; Professor Chris Jones
- Where: Dana-Farber Cancer Institute, Boston, USA; The Institute of Cancer Research, London, UK
- When: January 2021 – December 2025
- Cost: £1,444,811 over five years
- Research type: Paediatric, High and Low grade, Academic
- Award type: Quest for Cures
What is it?
Gliomas are the most common group of brain tumours in childhood. Researchers believe that childhood cancers are caused when mistakes happen in the normal programmes of development. This is especially so for gliomas, which are often characterised by mutations in a group of proteins called transcription factors. Transcription factors have important roles in the regulation of normal brain development.
In this project, Dr Beroukhim and his team at the Dana-Farber Cancer Institute, along with Prof. Chris Jones at The Institute of Cancer Research, will investigate how, in children’s brain tumours, two specific transcription factors switch on developmental pathways that would normally be switched off. They will also determine how to switch off these transcription factors using new treatments.
Additionally, Dr Beroukhim and Professor Jones are collaborating with other leading researchers to develop new drugs that can specifically destroy these transcription factors as another way to treat paediatric gliomas.
This collaboration brings together investigators with diverse areas of expertise, including glioma and developmental biology, genomics and epigenomics and chemistry. They will use sophisticated model systems of paediatric gliomas to understand how mutations in transcription factors affect developmental pathways. The researchers will also use genetic and epigenetic methods to understand how these changes affect the other regulatory structures of cells, and the team’s chemists will develop strategies to degrade these proteins as a way to therapeutically ‘switch them off’.
Why is it important?
Brain tumours are the leading cause of cancer-related morbidity and death in childhood. While children with low grade gliomas are more likely to survive, they can be left devastated by both the tumours themselves and the treatments required to cure them. Children diagnosed with high grade gliomas face a fight for life, with a dismal prognosis. Better treatments for all gliomas are desperately required. This research will be directed to understanding how cancers hijack normal developmental processes and how this can be targeted in new treatments for children diagnosed with gliomas.
Who will it help?
This work is driving us towards a future where children diagnosed with a brain tumour, regardless of grade, have more effective, less harmful treatments available.
We look forward to sharing the achievements of this project as it progresses.
Research is just one other way your regular gift can make a difference
Research is the only way we will discover kinder, more effective treatments and, ultimately, stamp out brain tumours – for good! However, brain tumours are complex and research in to them takes a great deal of time and money.
Across the UK, over 100,000 families are facing the overwhelming diagnosis of a brain tumour and it is only through the generosity of people like you can we continue to help them.
But, by setting up a regular gift – as little as £2 per month – you can ensure that families no longer face this destructive disease.
In this section
Dr Rameen Beroukhim
Dr Beroukhim is an Associate Professor of Medicine in the Cancer Biology department of the Dana- Farber Cancer Institute. Additionally he is a practicing Neuro-ongologist and brings expertise of both the clinic and the lab to this work.
Professor Chris Jones
Professor Jones is the Group Leader of the Glioma Team at The Institute of Cancer Research in London. His research focuses on understanding the biology of high-grade children’s tumours and using that knowledge to test targeted treatments.